LABCORP HOLDINGS INC.
LHAPI behind this page
LH Q2 2025 request
Playground key active
/api/financials?ticker=LH&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 3,527.3 | 3,220.9 | +9.5% |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services · Operating Segments | 784.8 | 707 | +11.0% |
| Diagnostics · Operating Segments | 2,748.8 | 2,524.9 | +8.9% |
Show Geography breakouts |
|||
| US | 2,931.6 | 2,698.8 | +8.6% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | 6.3 | 11 | -42.7% |
| Cost of Revenue | 2,481.1 | 2,294.5 | +8.1% |
| Gross Profit | 1,046.2 | 926.4 | +12.9% |
| Selling, General & Administrative | 579.3 | 557.8 | +3.9% |
| Amortization Of Intangible Assets | 68.3 | 62.2 | +9.8% |
| Net Restructuring And Other Special Charges | 4.1 | 11.6 | -64.7% |
| Operating Income | 394.5 | 294.8 | +33.8% |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services · Operating Segments | 123.3 | 107.4 | +14.8% |
| Corporate | -139.2 | -180.3 | +22.8% |
| Diagnostics · Operating Segments | 482.8 | 441.5 | +9.4% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 606.1 | 548.9 | +10.4% |
| Interest Expense | -57.1 | -47.6 | -20.0% |
| Investment Income Net | 1.7 | 1.3 | +30.8% |
| Income Loss From Equity Method Investments | -1.7 | -0.3 | -466.7% |
| Other Non-Operating Income (Expense) | -32.7 | 19.5 | -267.7% |
| Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest | 304.7 | 267.7 | +13.8% |
| Income Tax Expense (Benefit) | 66.4 | 62.1 | +6.9% |
| Net Income | 238.3 | 205.6 | +15.9% |
| Net Income Loss Attributable To Noncontrolling Interest | -0.4 | -0.3 | -33.3% |
| Net Income | 237.9 | 205.3 | +15.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | 237.9 | 205.3 | +15.9% |
| EPS (Basic) | 2.85 | 2.44 | +16.8% |
| EPS (Diluted) | 2.84 | 2.43 | +16.9% |
| Comprehensive Income | 394.9 | 198.7 | +98.7% |
| Wtd Avg Shares (Basic) | 83.4 | 84.1 | -0.8% |
| Wtd Avg Shares (Diluted) | 83.9 | 84.3 | -0.5% |
| Labor And Related Expense (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services | 302.3 | 285.7 | +5.8% |
| Diagnostics | 1,155.1 | 1,072.6 | +7.7% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 647.3 | — | — |
| Accounts Receivable | 2,120.6 | — | — |
| Unbilled Contracts Receivable | 156.1 | — | — |
| Inventory | 508.1 | 441.8 | +15.0% |
| Prepaid Expense Current | 655.1 | 618 | +6.0% |
| Total Current Assets | 4,087.2 | 3,571.3 | +14.4% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,133.8 | 2,932.5 | +6.9% |
| Goodwill | 6,551.1 | — | — |
Show Business Segments breakouts |
|||
| Biopharma Laboratory Services | 1,385.2 | — | — |
| Diagnostics | 5,165.9 | — | — |
| Other Non-Current Assets | 633 | 638.8 | -0.9% |
| Total Assets | 18,059.9 | 16,712.3 | +8.1% |
| Intangible Assets | 2,925.7 | — | — |
Show Schedule Of Other Intangible Assets By Major Class [Axis] breakouts |
|||
| Customer Relationships | 2,612 | — | — |
| Noncompete Agreements | 73 | — | — |
| Other Intangible Assets | 14.6 | — | — |
| Patents, Licenses And Technology [Member] | 226.1 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 3,494.4 | — | — |
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | 160.4 | 17.5 | +816.6% |
| Current Liabilities | |||
| Accounts Payable | 793 | 760.6 | +4.3% |
| Accrued Liabilities | 835.8 | 707.5 | +18.1% |
| Deferred Revenue | 398 | 388.3 | +2.5% |
| Operating Lease Liability Current | 186.1 | 182.1 | +2.2% |
| Finance Lease Liability Current | 4.3 | 6.7 | -35.8% |
| Short Term Debt And Along Term Debt Current Maturities | 499.6 | — | — |
| Total Current Liabilities | 2,716.8 | 4,064.7 | -33.2% |
| Non-Current Liabilities | |||
| Long-Term Debt | 5,077.3 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Senior notes due 2029 and 2034 | 600 | — | — |
| Operating Lease Liabilities | 713.1 | 642.6 | +11.0% |
| Finance Lease Liability Noncurrent | 65.6 | 76.9 | -14.7% |
| Other Non-Current Liabilities | 643.2 | 483.9 | +32.9% |
| Total Liabilities | 9,570.5 | 8,691.5 | +10.1% |
| Other Liabilities | |||
| Deferred Income Taxes And Other Tax Liabilities | 354.5 | 376.1 | -5.7% |
| Noncontrolling Interest Mezzanine Equity | 16.7 | 15 | +11.3% |
| Stockholders' Equity | |||
| Common Stock | 7.5 | 7.7 | -2.6% |
| Additional Paid In Capital Common Stock | 1.8 | 12.5 | -85.6% |
| Retained Earnings | -8,498 | -8,177.6 | -3.9% |
| Accumulated Other Comprehensive Income | -34.6 | -192 | +82.0% |
| Total Stockholders' Equity | 8,472.7 | 8,005.8 | +5.8% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -34.6 | -192 | +82.0% |
| Additional Paid In Capital | 1.8 | 12.5 | -85.6% |
| Common Stock | 7.5 | 7.7 | -2.6% |
| Retained Earnings | 8,498 | 8,177.6 | +3.9% |
| Total Liabilities & Equity | 18,059.9 | 16,712.3 | +8.1% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 337.1 | 311.4 | +8.3% |
| Stock-Based Compensation | 66.9 | 62.4 | +7.2% |
| Depreciation And Amortization Of Leased Assets | 99.4 | 88.6 | +12.2% |
| Deferred Income Taxes | -12.2 | -39.1 | +68.8% |
| Other Operating Activities Cash Flow Statement | 46.1 | 36.6 | +26.0% |
| Change in Accounts Receivable | -139.9 | -192.2 | +27.2% |
| Increase Decrease In Contract With Customer Asset | 4.8 | 26.8 | -82.1% |
| Change in Inventory | -3.5 | 27.7 | -112.6% |
| Change in Prepaid & Other Assets | -57.8 | -21.6 | -167.6% |
| Change in Accounts Payable | -80.6 | -51.7 | -55.9% |
| Increase Decrease In Deferred Revenue | -8.7 | -30.8 | +71.8% |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -179.4 | -166.4 | -7.8% |
| Net Cash from Operations | 639.1 | 531.3 | +20.3% |
| Investing Activities | |||
| Capital Expenditures | -203.9 | -262 | +22.2% |
| Proceeds From Sale Of Property Plant And Equipment | 2.4 | 0.2 | +1100.0% |
| Proceeds From Sale Of Other Investments | 6.9 | — | — |
| Payments To Acquire Investments | 172 | 36.7 | +368.7% |
| Payments To Acquire Businesses Net Of Cash Acquired | -63.5 | -293.1 | +78.3% |
Show Business Acquisition breakouts |
|||
| BioReference Health (Oncology Focused) | -225 | — | — |
| Net Cash from Investing | -430.1 | -578.1 | +25.6% |
| Financing Activities | |||
| Repayments Of Senior Debt | -1,000 | — | — |
| Proceeds From Long Term Lines Of Credit | 64.8 | 951.9 | -93.2% |
| Repayments Of Lines Of Credit | -64.8 | -932.1 | +93.0% |
| Proceeds From Accounts Receivable Securitization | 225 | — | — |
| Tax Withholding for Share Compensation | 29 | 37.8 | -23.3% |
| Net Proceeds From Issuance Of Stock To Employees | 25.7 | 26.7 | -3.7% |
| Payments Of Dividends | 121.5 | 122.5 | -0.8% |
| Share Repurchases | 200 | 100 | +100.0% |
| Proceeds From Payments For Other Financing Activities | -7.3 | -7.9 | +7.6% |
| Net Cash from Financing | -1,107.1 | -221.7 | -399.4% |
| Supplemental | |||
| Income Taxes Paid | 146.7 | 153 | -4.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 26.7 | -3.2 | +934.4% |
| Net Change in Cash | -871.4 | -271.7 | -220.7% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 647.3 | 265.1 | +144.2% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.